<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19912">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776411</url>
  </required_header>
  <id_info>
    <org_study_id>FDS-J02</org_study_id>
    <nct_id>NCT01776411</nct_id>
  </id_info>
  <brief_title>Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients</brief_title>
  <official_title>Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma K.K.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I portion:

      To confirm safety and tolerability in recurrent/refractory peripheral T-cell lymphoma
      patients during repeated oral administration of forodesine 300 mg twice daily (600 mg/day)
      for 28 days, and determine the recommended dose. Also, to evaluate pharmacokinetics.

      Phase II portion:

      To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen
      determined in the phase I portion. The primary efficacy endpoint shall be objective response
      rate (ORR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective response rate (ORR) based on evaluation by image assessment committee</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Recurrent or Refractory PTCL</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients at least 20 years of age.

          -  Patients histologically diagnosed with peripheral T-cell lymphoma by pathological
             diagnosis of biopsied lesion. In this study, peripheral T-cell lymphoma is defined as
             the following mature T-cell/NK-cell neoplasms found in the 4th edition of the WHO
             Classification.

          -  Recurrent/refractory patients with a treatment history of at least one regimen.

          -  Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in
             two perpendicular directions and greater than 1.5 cm in maximum diameter on computed
             tomography performed.

          -  Patients expected to survive for at least 3 months.

          -  ECOG PS 0-1.

          -  Patients with adequate hemopoietic efficacy, liver and kidney function.

          -  Patients from whom written consent has been obtained prior to study initiation.

        Exclusion Criteria:

          -  Patients who received a chemotherapy agent or a high dose of a systemic
             adrenocorticosteroid within 21 days prior to initial administration of the study
             drug.

          -  Patients who received radiation therapy, phototherapy, or electron beam therapy
             within 21 days prior to initial administration of the study drug.

          -  Patients who received another study drug within 28 days prior to initial
             administration of the study drug.

          -  Patients who received antibody therapy within 100 days prior to initial
             administration of the study drug.

          -  Patients with a history of allogeneic hematopoietic stem cell transplantation. Or
             patients with a history of autologous hematopoietic stem cell transplantation within
             100 days prior to initial administration of the study drug.

          -  Patients with cerebral metastasis or central nervous system lesion or a past history.

          -  Patients with active multiple primary cancer. Or patients with a history of a
             malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years.

          -  Patients with severe cardiovascular disease.

          -  Patients with congenital long QT syndrome.

          -  Patients with QTcF &gt;0.48 sec.

          -  Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological
             investigation. Or patients positive for either HBc antibody or HBs antibody, and
             showing DNA more than sensitivity in HBV-DNA assay.

          -  Patients positive for CMV antigen on immunological investigation.

          -  Patients with infectious disease requiring treatment consisting of intravenous
             administration of antibacterial agent, fungicide, or antiviral drug.

          -  Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to
             have insufficient pulmonary function.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kensei Tobinai, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiki Uchida, MD, PhD</last_name>
      <phone>+81-52-832-1121</phone>
    </contact>
    <investigator>
      <last_name>Toshiki Uchida, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirokazu Nagai, MD, PhD</last_name>
      <phone>+81-52-951-1111</phone>
    </contact>
    <investigator>
      <last_name>Hirokazu Nagai, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunihiro Tsukasaki, MD, PhD</last_name>
      <phone>+81-4-7133-1111</phone>
    </contact>
    <investigator>
      <last_name>Kunihiro Tsukasaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime,</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isao Yoshida, MD, PhD</last_name>
      <phone>+ 81-89-999-1111</phone>
    </contact>
    <investigator>
      <last_name>Isao Yoshida, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norifumi Tsukamoto, MD, PhD</last_name>
      <phone>+81-27-220-8529</phone>
    </contact>
    <investigator>
      <last_name>Norifumi Tsukamoto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitsutoshi Kurosawa, MD, PhD</last_name>
      <phone>+81-11-811-9111</phone>
    </contact>
    <investigator>
      <last_name>Mitsutoshi Kurosawa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tohru Murayama, MD, Ph.D</last_name>
      <phone>+81-78-929-1151</phone>
    </contact>
    <investigator>
      <last_name>Tohru Murayama, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1143</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiyoshi Ando, MD</last_name>
      <phone>+81-463-93-5083</phone>
    </contact>
    <investigator>
      <last_name>Kiyoshi Ando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Ishizawa, MD, PhD</last_name>
      <phone>+81-22-717-7772</phone>
    </contact>
    <investigator>
      <last_name>Kenichi Ishizawa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirohiko Shibayama, MD, Ph.D</last_name>
      <phone>+81-6-6879-3871</phone>
    </contact>
    <investigator>
      <last_name>Hirohiko Shibayama, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junji Suzumiya, MD, PhD</last_name>
      <phone>+81-853-23-2111</phone>
    </contact>
    <investigator>
      <last_name>Junji Suzumiya, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tohru Izumi, MD,PhD</last_name>
      <phone>+81-286- 58-5669</phone>
    </contact>
    <investigator>
      <last_name>Tohru Izumi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kensei Tobinai, MD, PhD</last_name>
      <phone>+81-3-3542-2511</phone>
    </contact>
    <investigator>
      <last_name>Kensei Tobinai, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital Japanese Foundation for Cancer Research</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550,</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiyohiko Hatake, MD, PhD</last_name>
      <phone>+81-3-3520-0111</phone>
    </contact>
    <investigator>
      <last_name>Kiyohiko Hatake, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Yamauchi, MD, Ph.D, FACP</last_name>
      <phone>+81-776-61-3111</phone>
    </contact>
    <investigator>
      <last_name>Takahiro Yamauchi, MD, Ph.D, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naokuni Uike, MD</last_name>
      <phone>+81-92-541-3231</phone>
    </contact>
    <investigator>
      <last_name>Naokuni Uike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuo Tamura, MD, PhD</last_name>
      <phone>+81-92-801-1011</phone>
    </contact>
    <investigator>
      <last_name>Kazuo Tamura, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imamura Bun-in Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atae Utsunomiya,, MD, PhD</last_name>
      <phone>+81-99-251-2221</phone>
    </contact>
    <investigator>
      <last_name>Atae Utsunomiya, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michihiro Hidaka, MD, PhD</last_name>
      <phone>+81-96-353-6501</phone>
    </contact>
    <investigator>
      <last_name>Michihiro Hidaka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masafumi Taniwaki, MD, PhD</last_name>
      <phone>+81-75-251-5651</phone>
    </contact>
    <investigator>
      <last_name>Masafumi Taniwaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama,</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshinobu Maeda, MD, PhD</last_name>
      <phone>+81-86-233-7151</phone>
    </contact>
    <investigator>
      <last_name>Yoshinobu Maeda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
